Bone loss often occurs as a side effect in men who receive hormone-deprivation therapy for their advanced prostate cancer.

However, according to a new study, bone-strengthening drugs Fosamax may help to avoid the damage.

Earlier it was found that the drug prevent bone loss in patients on hormone-deprivation therapy. And now the current follow-up shows that two years of the drug offers even greater protection to men.

Dr. Neil M. Resnick, who is a professor of medicine in the department of geriatrics in Pittsburg University, says that: “In aging population, the risk of age related diseases is greatly increasing and prostate cancer is one of the commonest among these risks.”

Resnick further added, “Usually patients with prostate cancer are placed on an androgen-deprivation therapy as testosterone is considered a cause to spur prostate cancer. This good thing about the therapy is that it works in most of the patients.”

“But the therapy also has some side effects and the worst one is osteoporosis that occurs because of the drug that blocks body’s ability to produce androgens.”

The study authors told that the use of therapy has greatly increased over the past decade. The risk of bone loss due because of the therapy is quite high during the first year of treatment and it’s long term use also increase the men’s fracture risk more.

The study will be published in the Journal of Clinical Oncology in the Sept.20 issue.

All articles published in AllinfoDir Articles are property of the site only, copying and publishing is strictly against the policy of the site and strictly prohibited.